Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 5/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.50 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.50 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7935130 | 1.00 | GRIN2D (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL288281 | 1.00 | GRIN2D (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL288282 | 1.00 | GRIN2D (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL5980862 | 0.98 | GRIN2D (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL5605868 | 0.98 | GRIN2D (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL503347 | 0.98 | GRIN2D (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2651847 | 0.98 | GRIN2D (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL123134 | 0.98 | GRIN2D (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Hydrochloric Acid SCHEMBL27984582 | 0.98 | GRIN2D (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2652715 | 0.98 | GRIN2D (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 661 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4274838-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | BICYCLETX LTD (GB) | 2024-09-25 | — | — | EP | claimed |
| WO-2024148312-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR AMINO ACID SYNTHESIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-07-11 | — | — | WO | claimed |
| US-20240197896-A1 | SYNTHETIC PEPTIDE SHUTTLE AGENT BIOCONJUGATES FOR INTRACELLULAR CARGO DELIVERY | FELDAN BIO INC. (CA) | 2024-06-20 | — | — | US | claimed |
| US-20240108738-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | BICYCLETX LIMITED (GB) | 2024-04-04 | — | — | US | claimed |
| CN-117750978-A | Synthetic peptide shuttle bioconjugates for intracellular cargo delivery | 费尔丹生物公司 | 2024-03-22 | — | — | CN | claimed |
| EP-4313159-A1 | SYNTHETIC PEPTIDE SHUTTLE AGENT BIOCONJUGATES FOR INTRACELLULAR CARGO DELIVERY | Feldan Bio Inc. (CA) | 2024-02-07 | — | — | EP | claimed |
| CN-117529489-A | Bicyclic peptide ligands specific for NK cells | 拜斯科技术开发有限公司 | 2024-02-06 | — | — | CN | claimed |
| US-20230399661-A1 | SHUTTLE AGENT PEPTIDES OF MINIMAL LENGTH AND VARIANTS THEREOF ADAPTED FOR TRANSDUCTION OF CAS9-RNP AND OTHER NUCLEOPROTEIN CARGOS | FELDAN BIO INC. (CA) | 2023-12-14 | — | — | US | claimed |
| US-20230383291-A1 | PEPTIDE-BASED TRANSDUCTION OF NON-ANIONIC POLYNUCLEOTIDE ANALOGS FOR GENE EXPRESSION MODULATION | FELDAN BIO INC. (CA) | 2023-11-30 | — | — | US | claimed |
| EP-4274838-A2 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | BicycleTx Limited (GB) | 2023-11-15 | — | — | EP | claimed |
| WO-2020120984-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | BICYCLETX LIMITED (GB) | 2020-06-18 | — | — | WO | claimed |
| CN-110799547-A | Compounds for treating, ameliorating or preventing neurological-related disorders and uses thereof | 拜西欧斯（北京）生物技术有限公司 | 2020-02-14 | — | — | CN | claimed |
| US-20190177370-A1 | PEPTIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, OR PRODRUG THEREOF | TOKYO UNIVERSITY OF PHARMACY & LIFE SCIENCES (JP) | 2019-06-13 | — | — | US | claimed |
| WO-2019051327-A2 | AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2019-03-14 | — | — | WO | claimed |
| EP-3335720-A1 | C-DI-GMP BINDING PEPTIDES | Universität Basel (CH) | 2018-06-20 | — | — | EP | claimed |
| EP-2788359-B1 | COMPOSITION AND METHOD FOR NEUROPEPTIDE S RECEPTOR (NPSR) ANTAGONISTS | RES TRIANGLE INST (US) | 2017-03-01 | — | — | EP | claimed |
| US-9150582-B2 | Composition and method for neuropeptide S receptor (NPSR) antagonists | RESEARCH TRIANGLE INSTITUTE (US) | 2015-10-06 | — | — | US | claimed |
| US-20150057268-A1 | COMPOSITION AND METHOD FOR NEUROPEPTIDE S RECEPTOR (NPSR) ANTAGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2015-02-26 | — | — | US | claimed |
| EP-2788359-A1 | COMPOSITION AND METHOD FOR NEUROPEPTIDE S RECEPTOR (NPSR) ANTAGONISTS | Research Triangle Institute (US) | 2014-10-15 | — | — | EP | claimed |
| WO-2013086200-A1 | COMPOSITION AND METHOD FOR NEUROPEPTIDE S RECEPTOR (NPSR) ANTAGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2013-06-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057268-A1 | COMPOSITION AND METHOD FOR NEUROPEPTIDE S RECEPTOR (NPSR) ANTAGONISTS | NPSR1, TACR1, NPFFR1 | GRIN2D 731/4885GRIN3B 346/4885GRIN1 436/4885 |
| US-20240197896-A1 | SYNTHETIC PEPTIDE SHUTTLE AGENT BIOCONJUGATES FOR INTRACELLULAR CARGO DELIVERY | SCAMP2, SLC7A1, NUMA1 | GRIN2D 4341/4885GRIN3B 3703/4885GRIN1 3039/4885 |
| US-20190177370-A1 | PEPTIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, OR PRODRUG THEREOF | MYOF, MSTN, VIP | GRIN2D 4832/4885GRIN3B 3628/4885GRIN1 3450/4885 |
| US-20240108738-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | PBK, KLRK1, MICA | GRIN2D 3525/4885GRIN3B 1200/4885GRIN1 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.